Exposure of mammalian cells to hypoxia, radiation and certain chemotherapeutic agents promotes cell cycle arrest and/or apoptosis. Activation of p53 responsive genes is believed to play an important role in mediating such responses. In this study we identi®ed a novel gene, PA26, which maps to chromosome 6q21 and encodes at least three transcript isoforms, of which two are dierentially induced by genotoxic stress (UV, girradiation and cytotoxic drugs) in a p53-dependent manner. A functional p53-responsive element was identi®ed in the second intron of the PA26 gene, in consistence with a mechanism of transcriptional induction of the PA26 gene by p53. No clues to its functions were revealed by sequence analysis, although pronounced negative regulation by serum factors argues for a potential role of PA26 in growth regulation. Immunological analysis suggests that PA26 protein(s) is localized to the cell nucleus. Our results suggest that the PA26 gene is a novel p53 target gene with properties common to the GADD family of growth arrest and DNA damageinducible stress-response genes, and, thus, a potential novel regulator of cellular growth.
Introduction
Inactivation of the p53 tumor suppressor protein contributes to the progression of a wide range of human tumors, and is the most frequently mutated tumor suppressor to be identi®ed in human cancers (Hollstein et al., 1991) . The ability of p53 to inhibit cell growth in response to common cellular stresses such as hypoxia and DNA damage, is a major function associated with its role as a tumor suppressor and guardian of the genome' (Lane, 1992) . Increased genomic instability, defects in DNA repair processes, loss of cell cycle check point controls, and defects in the activation of programmed cell death are common features associated with loss of p53 function and tumor progression.
Multiple cellular functions of p53 appear to be associated with its ability to induce and regulate cell cycle arrest and apoptosis (reviewed by Levine, 1997) . Among these, the most well documented biochemical property of p53 is its ability to bind to speci®c DNA sequences and activate the transcription of select target genes. Accordingly, the mdm-2 gene has been shown to encode an oncoprotein that interacts with p53, promotes its degradation, and thus represents a critical player in p53 feedback regulation (Momand et al., 1992; Oliner et al., 1993; Finlay et al., 1993; Chen et al., 1996; Haupt et al., 1997; Kubbutat et al., 1997) . p21/WAF1, mediates p53-induced cell cycle arrest (ElDeiry et al., 1993) . Gadd45 inhibits cell growth and has been implicated in DNA repair processes (Smith et al., 1994) . Bax, a member of the bcl-2 family of cell death regulators, promotes apoptosis (Miyashita and Reed, 1995) , while Killer/DR5 is a death receptor gene member of the TNFR family (Wu et al., 1997) . IGFBP-3 encodes an inhibitor of insulin-like growth factors, and provides a mechanism whereby p53 may interfere with the mitogenic and survival functions of insulin-like growth factors, thereby sensitizing cells to apoptosis (Buckbinder et al., 1995; Rajah et al., 1997) . Most recently, a signi®cant number of additional p53 response genes have been identi®ed, including: A28-RGS14, a GAP (GTPase activating protein) which inhibits G-protein-coupled receptor-mediated activation of the MAPK pathway upstream of ras (Buckbinder et al., 1997) ; Wip1, a type 2C protein phosphatase with growth inhibitory function (Fiscella et al., 1997) . Other less well characterized p53-responsive genes include cyclin G (Okamoto et al., 1994) , CGR11 and CGR19 (Madden et al., 1996) , BTG2 (Roulault et al., 1996) , the putative tumor suppressor gene Hic-1 (Wales et al., 1995) , and the nuclear zinc ®nger protein PAG608 (Israeli et al., 1997) . A comprehensive SAGE analysis of dierentially expressed transcripts in p53-expressing versus nonexpressing colon carcinoma cells revealed additional genes seemingly induced by p53 (Polyak et al., 1997) . Among the most highly induced genes, several encoded proteins that could either generate or respond to oxidative stress, leading to the intriguing hypothesis that induction of the formation of reactive oxygen species could be a process whereby p53 promotes cell death. Whether most of these genes are directly or indirectly activated by p53, however, remains to be determined.
As evidenced by the studies cited above, the transcriptional activation of target genes represents a major function of p53. Thus, we have utilized a previously described dierential cDNA subtraction methodology (Buckbinder et al., 1994) to continue identifying and characterizing novel genes directly induced by wild type p53. We report here the identi®cation of a gene, named PA26, that is a novel p53 target gene and member of the GADD family of Growth Arrest and DNA Damage inducible genes.
Results

Identi®cation of PA26 as a p53-response gene
Saos-2D4H osteosarcoma cells that express an inducible p53-transgene encoding a temperature-sensitive mutant of p53 (p53V143A), were used as a model system to identify novel p53 target genes using a subtractive cDNA cloning approach, as previously described (Buckbinder et al., 1994) . Multiple cDNA fragments derived from distinct p53-induced transcript were isolated. One cDNA fragment derived from a novel gene, named here PA26 (for p53-activated gene 26), was induced by wild type but not mutant p53. Northern blot analysis using this cDNA fragment revealed that the PA26 gene is widely expressed in adult human tissues, encoding two major transcripts of *4 kb and *2.6 kb, respectively ( Figure 1a) .
Several experiments were performed to con®rm the identity of PA26 as a p53 response gene. A cDNA fragment spanning the sequence that was identi®ed by subtractive cloning, was used as a probe in Northern blot analysis. Figure 1b shows induction of PA26 mRNA in response to p53 induction in EB1 colon carcinoma cells which harbor a wild type p53-encoding transgene under the control of the metallothionein promoter (Shaw et al., 1992) . Consistent with the multi-tissue Northern blot analysis, two PA26 transcripts of *4 kb and *2.6 kb were detected, of which, however, only the *2.6 kb transcript was apparently induced by p53. The magnitude and time course of induction is comparable to that observed for mRNAs encoded by known p53-response genes, such as p21/ WAF1 and hdm-2 (not shown). Interestingly, despite sustained p53 mRNA and protein levels, induction of target genes mRNA was transient. Similar kinetics of p53 target gene expression were previously reported for other p53 expression systems (Buckbinder et al., 1994 : Madden et al., 1996 , suggesting the involvement of feedback mechanisms in p53 transcription function such as that regulated by hdm-2 (Momand et al., 1992) .
Consistent with the identi®cation of the PA26 gene in a screen for p53 regulated target genes, the treatment of cells with a variety of genotoxic agents resulted in pronounced induction of PA26 mRNA in a p53-dependent manner. Accordingly, exposure of normal human diploid ®broblasts (WI38) to the anticancer agent doxorubicin, UV-radiation or gradiation, resulted in a marked induction of the *2.6 kb PA26 transcript (Figure 1c) . Although not identical, the pro®le of induction was similar to that observed for other p53 response genes such as p21 and (Shaw et al., 1992) was induced by the addition of CdCl 2 (6 mM) to the cell culture medium. Induction of p53 protein was analysed by Western blot analysis using the DO1 monoclonal antibody (Calbiochem) and is shown in the lower panel. (c) Kinetics of PA26 mRNA induction in normal diploid human ®broblasts (WI-38 cells) treated with dierent genotoxic agents. Semicon¯uent WI-38 cells were treated with either 0.3 mM doxorubicin, 50 J/m 2 of ultraviolet light, or 6 Gy of gamma radiation hdm-2. The kinetics of induction diered depending on the type of genotoxic insult, consistent with the course of events leading to DNA strand break under these conditions. g-radiation-induced strands breaks occur rapidly in cells (as they are rapidly repaired), whereas strand break/repair in response to UV-induced thymidine-dimer formation is a delayed process. Comparably, rapid induction of PA26 mRNA expression was observed in response to g-radiation. In contrast, induction by UV radiation was comparably slow but sustained beyond 48 hr post-irradiation. Induction in response to continuous doxorubicintreatment was rapid and sustained, consistent with the mechanism of action of this anticancer agent. These results are consistent with the model that activation of the PA26 gene occurs in response to DNA strand breaks and correlates with p53 induction and activation.
The eect of p53 status on the response of PA26 gene expression to DNA damaging agents was further characterized in cells of diering p53 genotypes and those harboring p53-inactivating viral proteins. As shown in Figure 2 , induction of the 2.6 kb PA26 transcript is speci®c to cells expressing wild type p53 (U-87, MCF-7 wt and #6, WI38, RKO). No signi®cant induction was observed in cells either lacking p53 protein expression (p53 null: HL-60, Saos-2, EB), expressing mutant p53 protein (T-98G, MCF-7AdrR), or in which p53 is targeted for inactivation by SV40 T antigen (VA13) or for degradation by the human papilloma virus protein HPV-E6 (RKO-E6). The basal levels of PA26 mRNA were found to vary somewhat with cell type and cell culture conditions, which is likely to re¯ect the complex regulation of this gene by both p53-dependent and independent mechanisms. Similar observations were made for other p53 response genes. Collectively, a tight correlation between wild type p53 induction/activation (data not shown) and induction of PA26 mRNA by genotoxic stress was observed, consistent with PA26 being a physiologically relevant p53 stress-response gene.
Cloning and characterization of the PA26 gene: identi®cation of multiple alternative gene transcripts Northern blot analysis indicated that the PA26 gene may encode at least two distinct transcripts. Screening of cDNA libraries and 5'RACE allowed the isolation of cDNAs derived from three distinct PA26 transcripts (T1, T2 and T3), all diering at their 5' ends but sharing a common region of 2495 bp at their 3' ends, which includes the 3'UTR. A P1 genomic clone spanning a large region of the PA26 gene, including the 3'UTR, was subsequently analysed to determine the genomic structure of the PA26 gene and the origin of Figure 3 Genomic organization of the human PA26 gene and encoded proteins. (a) Schematic representation of the partial PA26 gene structure and encoded transcripts. White boxes correspond to exons 5 ± 12, which encode the core region common to all PA26 transcripts. Exon 4 (also common to all transcripts), is indicated in black, and is only translated in the transcripts T1 and T2, as indicated. Exons 1 ± 3, speci®c for each transcript, are indicated in dierent shades. The putative start codon for each transcript is also indicated. The location of a p53 binding site in intron II is marked as PA26-PRE. EcoRI sites (E) are also indicated. (b) Predicted amino acid sequences of PA26 proteins encoded by transcripts T1, T2 and T3. Top panel: Sequence of putative proteins PA26-T2 and PA26-T3. The entire sequence is the predicted sequence of protein PA26-T2. Underlined is the sequence predicted by exon 4, which is part of the PA26-T2 protein. Protein PA26-T3 starts at the putative start methionine and its entire sequence is highlighted in bold letters. Lower panel: Shows the sequence of the N-terminus of the predicted PA26-T1 protein. Underlined is the translated sequence encoded by exon 4, which is common to the PA26-T2 and PA26-T1 proteins. Dotted lines indicate that the rest of the sequence is identical to that shown for PA26-T2 and PA26-T3 in the top panel the alternative transcripts T1, T2 and T3. Figure 3a shows the partial genomic structure of the PA26 gene, encompassing 12 coding exons. Exons 2 through 12 were contained within P1 clone 4759, and thus, physically linked. Exon 2 and exon 3 represent the dierentially spliced/expressed exons present in transcripts T2 or T3, respectively. Exon 1, which is linked to exon 4 in transcript T1, could not be physically linked, indicating that the PA26 gene spans a region greater than *20 kb. Combined sequence analysis of the cloned cDNAs and exons contained within the genomic P1 clone, revealed that transcripts T1, T2 and T3 predict proteins with diering N-termini and a common core region and C-terminus ( Figure 3b ). Transcript T3, predicts a protein of 426 amino acids (predicted MW of 46 kDa) which is encoded by the region common to all transcripts (exons 4 ± 12). An inframe stop codon was identi®ed within the 3' end of exon 3. In contrast, based on an in-frame ORF generated by splicing of exon 2 to exon 4, transcript T2 predicts a protein of 491 residues (predicted MW of 55 kDa). An in-frame stop codon was identi®ed upstream of the putative start codon within exon 2. Similarly, based on an in-frame ORF generated by splicing of exon 1 to exon 4, transcript T1 predicts a protein of 551 residues (predicted MW of 63 kDa). Although no in-frame stop codon was identi®ed in the available T1 cDNA sequence, analysis of a mouse T1 PA26 cDNA revealed sequence divergence and an inframe stop codon immediately adjacent to the conserved and predicted start methionine (data not shown). The predicted protein sequences share no signi®cant homology to known proteins, and did not reveal any clue about the potential function of the PA26 gene.
Dierential induction of alternative PA26 transcripts by p53
Based on the identi®cation of three PA26 transcript isoforms by cDNA cloning, dierential hybridization and RT-PCR experiments were performed to determine which transcript species was represented within the induced *2.6 kb PA26 mRNA`band' identi®ed by Northern blot analysis. 5' end cDNA probes speci®c for T1 identi®ed it as a non-induced *4 kb band on Northern blots derived from cadmium-stimulated EB1 cells as well as DNA damaged cells. In contrast, probes speci®c for T2 detected the predominant *2.6 kb band induced in response to p53, whereas no signal was detected with probes speci®c for T3 (data not shown). These ®ndings suggested that T2 is the predominant transcript induced by p53. These results were con®rmed by RT ± PCR analysis using primer pairs selected for T1, T2 or T3 and RNA from uninduced vs CdCl 2 induced EB-1 cells and untreated vs doxorubicin treated RKO cells. As shown in Figure  4 , T2 and T3 were speci®cally induced in response to p53-induction in EB1 and RKO cells. In contrast, T1 was not induced (all RT ± PCR products were con®rmed by sequence analysis). Whereas only one round of PCR ampli®cation was required to detect T2, two rounds of PCR ampli®cation were necessary to detect T3-derived RT ± PCR products, consistent with low expression observed in Northern blot analysis (data not shown), and indicating that PA26-T2 represents the major p53-induced PA26 transcript in human cells.
Induction of PA26 protein expression by p53
To determine expression levels, cellular localization and regulation of endogenous PA26 protein(s), a comparative analysis of PA26 proteins generated by in vitrotranslation and cellular proteins detected by an anti-PA26 peptide polyclonal antibody, was performed. Figure 5a shows proteins generated by in vitro transcription/translation of T1, T2 and T3 cDNAs. Consistent with the predicted molecular weights of the PA26 protein variants, proteins of *68 kD (for PA26-T1), *55 kD (for PA26-T2) and *48 kD (for PA26-T3), were detected. Additional smaller protein products were detected, and could represent degradation products or, alternatively, products resulting from the use of alternative translation start sites. Cellular PA26 protein(s) derived from cadmium chloride stimulated EB1 colon carcinoma cells (induced p53) was subsequently analysed by cell fractionation and Western blot analysis using an anity-puri®ed anti-PA26 peptide antibody. As shown in Figure 5b , an apparent speci®c *57 kD protein was detected in the nuclear fraction of induced EB1 cells, consistent with the previous ®ndings that the PA26-T2 transcript, which predicts a *55 kD protein, is the predominant p53-induced transcript in EB1 cells and other cell types ( Figure 5) . A weak signal for a noninduced *70 kD protein was also detected, and may represent the protein encoded by the transcript PA26-T1 not induced by p53. A his-tagged PA26-T1 recombinant protein expressed in baculovirus was used as a positive control. The dierence in mobility between his-PA26-T1 and its cellular counterpart by SDS ± PAGE may be due to post-translational modi®cation, possibly phosphorylation. Indeed, there are several potential phosphorylation sites in the PA26 protein including those for protein kinases C and A, Ca-calmodulin dependent-kinases, casein kinase II and tyrosine kinases. In summary, these results strongly suggest that the major p53-induced transcript, PA26-T2, encodes a nuclear protein.
Identi®cation of a p53 response element (PA26-PRE)
The dierential induction of transcripts T2 and T3 by p53, and the distance of exons 2 and 3 relative to exon 1, raise the question as to whether T1 and T2 expression is under the control of an intragenic p53-inducible promoter. To further examine this issue, and to determine whether the PA26 gene is a direct target of p53, we searched for a p53-responsive element within the PA26 gene.
Sequence analysis of the cloned *20 kb PA26 genomic region revealed a potential p53 binding site, PA26-PRE, within intron 2 (Figures 2a and b) . This site diverges by two nucleotides from the consensus p53 binding site RRR(A/T)(A/T)GYYY , a feature common to many previously reported p53 responsive elements. EMSA (electrophoretic mobility shift assay) analysis using puri®ed human p53 protein and anti-p53 monoclonal antibodies, con®rmed this DNA element as a speci®c p53 binding site. Accordingly, a wild type but not mutant consensus oligonucleotide competed for binding to p53 (Figure 6b) . Furthermore, when cloned upstream of a heterologous promoter driving expression of a luciferase reporter gene, the PA26-PRE conferred inducibility by wild type but not mutant p53 upon transfection of Saos-2 osteosarcoma cells ( Figure  6c ). These ®ndings con®rm that the PA26-PRE is a functional p53 response element. Considering that only T2 and T3 transcripts are induced by p53 (see Figure  4) , these ®ndings raise the possibility that an intragenic promoter within the PA26 gene is associated with the selective induction of these transcripts by p53, a phenomenon previously described for the mdm-2 gene (Barak et al., 1994) .
Regulation of PA26 gene expression by growth arrest
Previous studies have shown that a subgroup of DNA damage-inducible genes are also upregulated by growth arrest signals such as serum deprivation (Fornace et al., 1988 (Fornace et al., , 1989 . These genes have been named GADD genes (for Growth Arrest and DNA Damage inducible genes). One such gene, GADD45, has also been shown to be a p53-response gene (Kastan et al., 1992) . To test whether PA26 may be a novel GADD gene, normal diploid human ®broblasts (WI38) were serum starved and PA26 mRNA levels determined at various time points after serum withdrawal. As shown in Figure 7a , *2.6 kb PA26 transcripts are rapidly induced, peaking at *16 h but sustained beyond 48 h. In contrast, stimulation of serum deprived cells with 10% serum speci®cally repressed PA26 mRNA levels (Figure 7b) , as opposed to induction observed for c-fos mRNA. 490% inhibition was observed by 2 h post-stimulus. PA26 transcript levels rise again 16 h after serum stimulation, following a pattern of expression complementary to that of the delayed-early response genes (reviewed by Winkles, 1998) . These observations indicate that expression of PA26 is exquisitely sensitive to serum factors. Similar observations were made using the U-87 cell line (data not shown) as well as in mouse embryonic ®broblasts (in preparation).
Chromosomal localization of PA26
The chromosomal localization of PA26 was determined by somatic cell hybrid analysis and con®rmed by FISH analysis (Figure 8 PA26 Western blot analysis of fractionated protein extracts from EB-1 cells stimulated for 0, 6 or 12 h. with CdCl 2 . Immunoblotting was performed with an anity-puri®ed anti-PA26-peptide polyclonal antibody (300 ng/ml). The cytoplasmic fraction is indicated as CE, the soluble nuclear fraction as NE, and the insoluble fraction as UE (urea extract). The speci®city of the anti-PA26-peptide antibody was tested by preincubating the antibody with PA26-peptide for 30 min before incubation (lower panel). Baculovirus produced His-tagged-PA26-T1 protein was also analysed as a control (lane A). Lane L shows molecular weight markers arm of a group Z chromosome. In a second experiment a biotinylated probe which is speci®c for the centromere of chromosome 6 (D6Z1), was cohybridized with clone 4755. This experiment resulted in the speci®c labeling of the centromere of chromosome 6. Analysis of ten speci®cally hybridized chromosomes 6 demonstrated that 4755 is located at a position which is 39% of the distance from the centromere to the telomere of chromosome arm 6q, an area that corresponds to band 6q21. A total of 80 metaphase cells were analysed, with 77 exhibiting speci®c labeling. No other signi®cant signal cluster was detected on any other chromosome. A computer search against the Human Transcript Map (Shuler et al., 1996) identi®ed a region of 173 bp in the cDNA marker A007I12 located between map positions D6S301 and D6S416 in the long arm of chromosome 6, further con®rming the chromosomal localization of A26 in the 6q21 region.
Discussion
Induction of p53 in response to hypoxia and DNA damage is a process that is intimately associated with cell fate of normal and tumorigenic cells. It constitutes an increase in p53 protein levels and the transition of p53 from a latent state to an active state with increased anity for speci®c p53-binding DNA elements contained within p53-responsive genes. Most tumorderived mutants of p53 are defective in sequencespeci®c DNA binding, lending support to the notion that the sequence-speci®c transcription activation function is an important component of the tumor suppressor activity of p53. In concordance, proteins encoded by p53 target genes have been shown to regulate various processes controlling growth and viability of tumor cells, such as cell cycle progression and programmed cell death.
In this study we report the cloning and characterization of a novel p53 target gene, PA26. It is widely expressed in human tissues and conserved during evolution, sharing 99% identity with murine PA26 (manuscript in preparation) at the amino acid level. Apparent mutually exclusive splicing of exon 1, 2 and 3 to exon 4 is associated with the expression of three alternative PA26 transcripts predicting proteins with diering N-termini. Intriguingly, p53 selectively induces only two of the three transcripts. Transcript PA26-T1 (+exon 1) is not induced by p53, whereas both PA26-T2 (+exon 2) and PA26 T3 (+exon 3) are highly induced by p53. Although the precise mechanism whereby p53 promotes dierential induction of PA26 transcripts remains unclear, the identi®cation of an intragenic p53-responsive element within intron 2 of the PA26 gene strongly suggests that induction occurs at the level of transcription activation. The functionality of this binding site in the context of the endogenous promoter, however, remains to be determined. Recent studies on the mechanism whereby p53 induces another known target gene, mdm-2, to PA26-PRE and p21/WAF1 p53 binding site. The binding reactions were performed in the absence or presence of monoclonal antibody PAb421, and absence or presence of excess cold wild type p53 consensus oligonucleotide or mutant PA26PRE oligonucleotides. (c) PA26-PRE confers p53 inducibility on a heterologous promoter in Saos-2 cells. Luciferase reporter constructs (2.5 mg) bearing either one copy of PA26-PRE, p21/WAF1 p53 binding site, a mutant consensus p53 binding site (MutCon), or multiples copies of the bacterial tet repressor binding site (pUCHC13-3), were cotransfected with expression constructs encoding wt p53, mutant p53-273 (Arg to His, codon 273) or pcDNA3 vector, respectively (0.5 mg). Cells were harvested 24 h post-transfection and assayed for luciferase activity (relative light units) revealed that p53 induces the expression of select mdm-2 gene transcripts via the speci®c induction of an intragenic promoter (Barak et al., 1994) . By analogy, this may be a mechanism whereby p53 induces the selective expression of PA26-T2 and PA26-T3. The predominant transcript induced by p53, PA26-T2, appears to encode a *55 kD nuclear protein.
The predicted sequence of PA26 proteins revealed no particular insights into the potential function or mechanism of action of the PA26 gene. However, proteins encoded by transcripts T2 and T3 are likely to play a role in the cellular stress response mediated by p53. We found that induction of PA26 gene expression is very sensitive to multiple genotoxic insults, such as gradiation, UV radiation and DNA damaging cytotoxic agents such as doxorubicin. The kinetics of induction of PA26 transcripts follows an expression pattern similar to that of transcripts encoded by other p53-response genes, such as p21/Waf1 and hdm-2. Thus, multiple stress signals may converge on the PA26 gene and promote its activation. Induction of PA26 correlates with the presence of wild type p53 in multiple cell types. Accordingly, disruption of p53 function by mutations in p53, or viral proteins such as SV40 Tag and human papilloma virus E6 protein, completely abrogates the DNA damage-dependent induction of PA26. These observations strongly suggest that a functional p53 is essential for the induction of PA26, which appears to occur at the level of transcription activation and mediated, at least in part, by a p53-responsive element within intron 2 of the PA26 gene. Whether post-transcriptional regulation plays an additional role in PA26 transcript regulation is unclear. Previous studies described regulation of mRNA turnover as a mechanism whereby the expression of certain DNA damage response genes (gadd genes) is regulated (Jackman et al., 1994) . Interestingly, the 3'UTR of PA26 mRNA contains several perfect and degenerate ARE sequences, which are known to regulate mRNA stability of genes involved in cellular growth control (Levine et al., 1993; Jackman et al., 1994) . However, whether these are functional motifs remains to be determined.
Previous studies indicated that a subset of genes induced in response to DNA damage, are also induced in response to serum starvation and growth arrest. Induction of transcripts encoded by these genes may occur at the level of transcription and/or posttranscriptionally. At least one of these growth arrest and DNA damage-induced genes (gadd genes), GADD45, is also a p53 target gene. Following a similar pattern, PA26 appears to be a novel member of this gadd gene family. Accordingly, expression of PA26 mRNA is induced in response to serum starvation, and repressed by addition of serum to starved cells. Thus, whereas growth arrest is associated with induction of PA26, growth stimulation is associated with repression of PA26 expression in dierent cell types. This eect appears to be independent of p53 (data not shown), indicating that additional stress and/or growth regulatory signaling pathways converge on the PA26 gene and/or its encoded transcripts. In light of the ®ndings that PA26 is both a p53 target gene and member of the gadd gene family, it is conceivable that it plays an important role in cellular growth control. Thus, characterization of the biological function of PA26 proteins is likely to provide further insights into signaling pathways regulating tumor cell growth.
Chromosomal mapping placed the PA26 gene on chromosome 6q21. Deletions in this region have been described in non-Hodgkin lymphoma (Ot et al., 1993; Johansson et al., 1995) , acute lymphoblastic leukemia (Gerard et al., 1997) bladder carcinoma (Brown et al., 1994) , ovarian (Pejovic, 1995; Orphanos et al., 1995a) and mammary carcinomas (Orphanos et al., 1995b; Sheng et al., 1996; Noviello et al., 1996) and squamous cell carcinomas of the head and neck (Rao et al., 1994) , indicating the presence of one or more tumorsuppressor genes. This possibility is supported by chromosome transfer experiments (Negrini et al., 1994; Sandhu et al., 1996; Morelli et al., 1997) which seem to suggest that the putative tumor suppressor gene in 6q21 may be functioning as a senescence gene. Whether mutational inactivation of PA26 occurs in such tumor types will be addressed in future studies.
Materials and methods
cDNA isolation and cloning
A PCR based cDNA library subtraction procedure was used to enrich for cDNA fragments derived from mRNAs induced by p53, as previously described (Buckbinder et al., 1994) . A cDNA fragment, named PA26, which detected a (a) Induction of *2.6 kb PA26 transcript by serum starvation. Semicon¯uent WI-38 ®broblasts (time t=0) were washed twice with 0.05% FCS/MEM and were grown in this medium for the indicated times. (b) Suppression of PA26 mRNA expression by serum. Semicon¯uent WI-38 ®broblasts were grown with (+FCS) or without serum (7FCS) for 24 h (t=0 h). After this time serum was added to serum-starved cells at a ®nal concentration of 10% and RNA was harvested at the indicated points (in hours) *2.6 kb p53-regulated transcript was further used as a probe to screen a human lung and brain cDNA library in lambda ZAPII (Stratagene). Several independent overlapping clones were identi®ed and isolated as pBluescript plasmids by phagemid rescue (Stratagene). Overlapping clones L25 and S2 spanned a region of *2.6 kb, which included 3'UTR and polyA tail. The predicted open reading frame extended to the 5' end of the cDNA and shared high homology to the ORF of a mouse PA26 cDNA (data not shown). Additional upstream sequence was obtained using 5'RACE (Clontech) with RNA obtained from CdCl 2 stimulated (10 h) EB1 cells (Buckbinder et al., 1994) . This allowed the identi®cation of three alternative transcripts with diering 5' sequences: T1, T2 and T3, generated by alternate splicing of exons 1, 2 and 3 to exon 4. Genomic sequences and intron-exon boundaries were obtained by long range genomic PCR and sequence analysis of a P1 clone spanning part of the PA26 locus. Shotgun cloning (BglII/BamHI/Sau3A digestion) of P1 sequences into pBluescript plasmid allowed the isolation of a genomic fragment that spanned a region encompassing exon 2 (contained within transcript T2), intron 2 and exon 3 (expressed in transcript T3). Combined sequence analysis of cDNA and genomic DNA identi®ed additional exon 2 sequence upstream of that identi®ed by cDNA analysis alone. Subsequent RT-PCR analysis using speci®c primers for exon 2, con®rmed that such upstream exon 2 sequence was expressed and contained within transcript T2. This resulted in the identi®cation of an in-frame stop codon in the T2 cDNA, and thus the predicted full length coding region of transcript PA26-T2. Sequencing of T3 cDNA revealed an in-frame stop codon within the 3' end of exon 3, indicating that the start methionine resides within exon 5 in this transcript. Sequencing of T1 cDNA did not reveal an inframe stop codon upstream of the extended in-frame ORF generated by splicing of exon 1 to exon 4. However, cloning of a mouse PA26-T1 cDNA revealed sequence divergence and an in-frame stop codon upstream of the putative conserved start methionine within exon 1, indicating that the full length coding region of transcript T1 was identi®ed. Genbank accession numbers are AF033122, AF033120, AF033121 and for T1, T2 and T3, respectively.
Plasmid construction
The conserved core region of the PA26 cDNA, comprising exons 4 to 12, was excised from pBluescript (Stratagene) with EcoRI/XhoI and cloned into pcDNA3 to generate PA26-pcDNA3 (Invitrogen). Transcript speci®c RT-PCRgenerated cDNA fragments were subsequently cloned into the EcoRI site of this construct to generate three distinct plasmids containing T1, T2 and T3 cDNAs. All constructs were sequenced in both directions by automated DNA sequencing (ABI) using vector and gene speci®c primers. Luciferase reporter constructs were prepared by cloning the p53 binding sites PA26-PRE, p21-PRE or MutCon sequences into pUCHC13-3, as previously described (Buckbinder et al., 1994) . p53 plasmids were previously described (Buckbinder et al., 1995) .
Cell culture and cell treatment
Saos-2 and Saos-2D4H osteosarcoma cells (Buckbinder et al., 1994) , EB1 colon carcinoma cells (Shaw et al., 1992) , RKO and RKO-E6 colon carcinoma cells were cultured as described (Buckbinder et al., 1994 (Buckbinder et al., , 1995 . WI-38 human embryonic lung ®broblasts, WI-38 VA13, a subclone of the WI-38 line transformed with SV40, T98G glioblastoma, U-87 astrocytoma, HL-60 promyelocitic leukemia and MCF-7 breast carcinoma cells were obtained from ATCC (Rock- Figure 8 Chromosomal localization of the PA26 gene. Fluorescence in situ hybridization (FISH) of normal human metaphase chromosomes derived from PHA stimulated lymphocytes. Co-hybridization was performed with P1 clone 4755 labeled with digoxigenin and a biotin labeled probe which is speci®c for the centromere of chromosome 6 (D6Z1). Speci®c labeling of the centromere was indicated by a red signal (thin arrow), whereas labeling with the PA26 P1 clone resulted in a green signal (thick arrow). The chromosomal interval in chromosome 6q21 to which a fragment of the 3' end of PA26 cDNA sequence (A007I12) was localized using a computer search against the`Human Transcript Map', is indicated between the markers D6S301 and D6S416 ville, MD, USA) and cultured as recommended. MCF7 Adr (Cowan et al., 1986) , carrying an ampli®ed Mdr-1 gene and expressing a mutant p53 protein, and MCF7 clone 6 (clonal population derived from the parental cells) were cultured as the parental MCF7 cells. Treatments were as follows: (1) Doxorubicin (in 5% DMSO) was added to exponentially growing cells at the indicated dosages and times (see Results); (2) UV irradiation at 50 J/m 2 was performed in a UV cross-linker (UV Stratalinker 2400, Stratagene); (3) Gamma irradiation experiments were performed with a 137 Cs source (Shephard Mark IV); (4) Serum starvation was performed in MEM supplemented with 0.05% FCS. Cells were incubated in this medium for the indicated time periods before harvesting.
Transfection of cells was performed using lipofectamine (GIBCO ± BRL). 3 mg of DNA per 5 ml of lipofectamine in Optimem (GIBCO ± BRL) was used to transfect 2.5610 5 Saos-2 cells. For luciferase reporter assays, 2.5 mg of luciferase reporter construct were cotransfected with 0.5 mg of either p53 or 273-p53 cloned into pcDNA-3 (Invitrogen), or pcDNA-3 vector alone. Three hours post-transfection, cells were incubated in medium supplemented with 10% FCS for 24 h before harvesting.
RNA and Northern blot analysis
Total cellular RNA was extracted from cultured cells according to standard procedures (Sambrook et al., 1989) . Northern blotting, random priming and hybridization conditions were as previously described (Buckbinder et al., 1995 (Buckbinder et al., , 1997 . Unless otherwise indicated 10 mg of total RNA were loaded per lane.
Semi-quantitative RT ± PCR analysis
One mg of total RNA was used for cDNA synthesis using a mixture of hexamers and oligo-dT, and Superscript II Reverse Transcriptase (GIBCO ± BRL). After this, each reaction was cleaned using the PCR-clean protocol (Qiagen). cDNAs were subsequently ampli®ed with Taq polymerase (Boehringer Mannheim) in the presence of 10 pmol of transcript-speci®c primers (5'-CTGCT-GGGCTGCAAGCAGTG-3' for T2, 5'-GACTCAGGG-GAAGAGATGATG-3' for T3, and 5'-GGAGAGAAT-GAAGTGAGATG-3' for T1) and a common 3' primer derived from the core region of PA26 cDNA (5'-ATGCAGGTTCATAAGTAGG-3'). To ensure that equal amounts of total RNA were used, an 18S ribosomal set of primers (Ambion) was used to amplify 500 bp of the 18S ribosomal RNA, in the presence and absence of competimers in a ratio 4 : 1 (competimer/18S primers), and under the same conditions as the PA26 cDNA ampli®cation reactions. The PCR conditions were established such that ampli®cation of the cDNAs was dependent on the concentration of the corresponding mRNA. This was achieved by testing the PCR reaction under two dierent annealing temperatures (558 and 588C), two dierent number of cycles (25 and 35) and controlling the concentration of template until linear conditions were achieved. Final conditions were of an annealing temperature of 558C for 15 s and 35 ampli®cation cycles. One-tenth of the PCR products were separated in a 1.2% agarose gel (SeaKem, FMC BioProducts) and stained with EtBr. In addition, ampli®ed cDNAs were blotted onto Nytran membranes (Schleicher & Schuell) , and detected by hybridization with a random primed [ 32 P]dCTP PA26 probe spanning exons 4 and 5.
DNA binding assays
Sequence-speci®c binding of p53 to DNA was assayed by EMSA as described previously . The following double stranded DNAs were used in the binding reactions: PA26PRE (5'-ggacaagtctccacaagttc-3') and p21PRE (5'-tcttgaacatgtcccaacatgttgccg-3'), representing the p53-binding sites in the PA26 gene and p21/WAF gene, respectively. Speci®c binding was determined by preincubating samples with either cold wild type p53 consensus (5'-ggacatgcccgggcatgtc-3') or mutant PA26PRE competitor oligonucleotide (MutCon5'-tcagatctcctgaattatggagaattatccccccgctcgagcgg-3') at 100-fold excess.
Luciferase assay
Luciferase activity was determined as described previously (Buckbinder et al., 1994) .
Western blot analysis
Protein extracts (30 mg) along with molecular weight markers (New England Biolabs) were fractionated on SDS [sodium dodecyl sulfate] polyacrylamide gel (8 ± 16%) (Novex). Proteins were electroblotted on Immobilon-P membrane (Millipore). Western blots were developed using the CDP-Star system (New England Biolabs) when using an anti-PA26 antibody, or the ECL-chemiluminescence system (Amersham) when using the DO-1 anti-p53 monoclonal antibody (Calbiochem), as recommended by the suppliers.
Recombinant proteins
His-tagged PA26-T1 fusion protein was generated by cloning of PA26-T1 cDNA into the pBlueBacHis vector (Invitrogen) and subsequent selection of recombinant baculoviruses. Extracts of infected Sf9 insect cells were prepared by lysing the cells at 08C for 30 min in RIPA buer (10 mM Tris-HCl [pH 8.0], 1% Triton X-100, 150 mM NaCl) containing protease inhibitors Complete (Boehringer Mannheim). Lysates were centrifuged at 14 000 g for 10 min, 48C. His-p53 fusion protein puri®cation was done as previously described .
Antibody preparation
Anti-PA26 antibody was raised against the peptide CDGGHTFRPPSVSN, representing amino acids 225 ± 236 of the core region of PA26-T2 protein. The peptide was conjugated to Keyhole limpet hemocyanin (KLH) via MCS [6-Maleimido-Caproic Acid N-Hydroxysuccinimide Ester] (Chiron Mimotopes Peptide Systems). Rabbits were injected with the peptide-KLH conjugate (2 mg) mixed with 1 : 2 (vol/vol) with complete Freund's adjuvant. A second similar immunization followed 2 weeks later, this time using Incomplete Freund's Adjuvant. The resulting sera were anity puri®ed by passing through a peptide anity column with peptide coupled to ThiopropylSepharose 6B (Pharmacia).
Preparation of cellular extracts
Cell fractionation experiments were done using a modification of the method of Dignam et al. (1983) . Brie¯y, semicon¯uent cells were washed twice with ice cold phosphate buered saline (PBS) and scraped from the culture dish. The cells were collected by centrifugation at 400 g for 10 min at 48C and the cell pellet resuspended in two volumes, and subsequent volumes corresponding to that of the original pellet, of Triton Lysis buer (10 mM Tris pH 8.0; 0.08% Triton X-100; 150 mM NaCl; 1 mM MgCl 2 ; 10 mM ZnCl 2 ; 1 mM Na 3 VO 4 ; 1 mM PMSF [phenylmethylsulfonyl¯uoride]; and 10 mg/ml Aprotinin), vortexed and incubated on ice for 5 min. The samples were then centrifuged at 500 g for 5 min and the supernatant, the cytoplasmic extract (CE), was collected. The pellet containing crude nuclei was resuspended in one volume in the Dignam extraction buer (20 mM HEPES [hydroxyethyl piperazineethanesulfonic acid] pH 7.4; 480 mM NaCl; 1.5 mM MgCl 2 ; 0.2 mM EDTA [ethylenediamide tetraacetate]; 0.5 mM DTT; 10 mM ZnCl 2 ; 1 mM Na 3 VO 4 ; 1 mM PMSF [phenylmethylsulfonyl¯uoride]; 10 mg/ml Aprotinin; 25% glycerol). The nuclear suspension was incubated on ice for 45 min and centrifuged at 14 000 g for 10 min. This supernatant is the nuclear extract (NE). The nuclear pellet was further resuspended in four volumes in 8 M Urea, kept on ice for 10 min. and centrifuged again at 14 000 g for 10 min. This urea extract (UE) is enriched in nuclear matrix and tightly associated proteins.
